An integrated approach to TNBC precision medicine should incorporate three critical dimensions: 1. PD-L1 expression profiling to assess baseline immune activation status, 2. TMB quantification to evaluate neoantigen load and immunogenic potential, and 3. Immune phenotyping at the single-cell level to characterize the heterogeneous tumor microenvironment architecture. The gene discussed is CD274; the disease is neoplasm.